Wolfe Research Assumes Acceleron Pharma (XLRN) at Outperform

July 19, 2021 6:47 AM EDT
Get Alerts XLRN Hot Sheet
Price: $178.75 --0%

Rating Summary:
    11 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 5 | Down: 6 | New: 23
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wolfe Research analyst Andrew Galler assumes coverage on Acceleron Pharma (NASDAQ: XLRN) with a Outperform rating and a price target of $183.00.

The analyst comments "We are assuming coverage of XLRN with an Outperform rating and $183 PT. In this deck, we discuss key investor debates such as our thoughts on sotatercept in STELLAR, the outlook for Reblozyl, and the early-stage pipeline."

For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.

Shares of Acceleron Pharma closed at $117.26 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage